Tina Marriott - Jan 26, 2023 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role: President and COO
Signature: /s/ Jonathan Golightly, attorney-in-fact
Stock symbol: RXRX
Transactions as of: Jan 26, 2023
Transactions value $: -$56,067
Form type: 4
Date filed: 1/27/2023, 04:03 PM
Previous filing: Dec 30, 2022
Next filing: Feb 3, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RXRX	Class A Common Stock	Options Exercise	$8.48K	+8K	+3.93%	$1.06^*	212K	Jan 26, 2023	Direct	F1
transaction	RXRX	Class A Common Stock	Sale	-$64.5K	-8K	-3.78%	$8.07	204K	Jan 26, 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RXRX	Stock Option (Right to Buy)	Options Exercise	$0	-8K	-1.42%	$0.00	554K	Jan 26, 2023	Class A Common Stock	8K	$1.06	Direct	F1, F3
holding	RXRX	Stock Option (Right to Buy)						159K	Jan 26, 2023	Class A Common Stock	0	$11.40	Direct	F4
holding	RXRX	Stock Option (Right to Buy)						4.78K	Jan 26, 2023	Class A Common Stock	0	$11.40	Direct
holding	RXRX	Stock Option (Right to Buy)						150K	Jan 26, 2023	Class A Common Stock	0	$2.48	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person.
F2	The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $7.95 to $8.31 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F3	Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date.
F4	The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F5	One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date.